

# Glucagon III

## Contributors

J.M. Amatruda, D. Bataille, D. Bennis, H.-P. Bode  
P.E. Cryer, C.F. Deacon, H.-C. Fehmann, N. Geary  
B. Göke, R. Göke, J.J. Holst, V. Iwanij, M.M. Johnson  
T. Kornfelt, P.J. Lefèbvre, J.N. Livingston, I. Møllerup  
M.A. Nauck, P. Oreskov, C. Ørskov, G. Paolisso, C. Pavoine  
F. Pecker, J. Philippe, A.J. Scheen, J. Skucas, G. Slama  
B. Thorens, H.V. Tøttrup, C. Widmann, G.P. Zaloga  
P. Zirinis

## Editor

Pierre J. Lefèbvre



Springer

# Contents

## CHAPTER 1

### **The Industrial Production of Glucagon**

I. MOLLERUP, T. KORNFELT, P. ORESKOV, and H.V. TØTTRUP

With 7 Figures .....	1
A. Introduction .....	1
B. Production .....	1
I. Expression and Fermentation .....	1
II. Recovery and Purification .....	1
1. Recovery .....	1
2. Purification .....	2
3. Aggregation .....	3
III. Pharmaceutical Preparations .....	3
C. Analysis of Recombinant Human Glucagon .....	3
I. Introduction .....	3
II. Identification .....	3
III. Purity .....	4
1. Microbiological Impurities .....	4
2. Water .....	5
3. Chemical Impurities .....	6
IV. Assay .....	9
D. Stability .....	9
References .....	10

## CHAPTER 2

### **The Glucagon Gene and Its Expression**

J. PHILIPPE. With 8 Figures .....	11
A. Introduction .....	11
B. Structure .....	12
I. The Glucagon Gene .....	12
II. Genes Encoding Peptide Hormones of the Glucagon Superfamily .....	14
C. Expression .....	17

I. Tissue-Specific Expression .....	17
II. A-Cell-Specific Expression .....	19
III. Regulation of Glucagon Gene Expression .....	23
1. Regulation by Insulin .....	23
2. Regulation by the Second Messenger cAMP .....	24
D. Conclusions .....	26
References .....	27

## CHAPTER 3

### **Preproglucagon and Its Processing**

D. BATAILLE. With 8 Figures .....	31
A. Introduction .....	31
B. Tissue-Specific Post-translational Processing of Proglucagon .....	32
I. Glucagon-Containing Peptides .....	32
II. Glucagon-Related Peptides .....	38
C. Role of Prohormone Convertases in Proglucagon Processing .....	39
D. Secondary, Postsecretory Processing of Proglucagon-Derived Peptides .....	41
I. Glucagon (19-29) or Miniglucagon .....	42
II. Oxyntomodulin (19-37) .....	44
E. Conclusions .....	44
References .....	46

## CHAPTER 4

### **The Glucagon Receptor Gene: Organization and Tissue Distribution**

V. IWANIJ. With 4 Figures .....	53
A. Introduction .....	53
B. Cloning of the Glucagon Receptor .....	53
C. Organization of the Glucagon Receptor Gene .....	60
D. Tissue Distribution of the Glucagon Receptors .....	61
I. Adipose Tissue Glucagon Receptors .....	61
II. Kidney Glucagon Receptors .....	62
III. Pancreatic Islets Glucagon Receptors .....	62
IV. Brain Glucagon Receptors .....	63
V. Heart Glucagon Receptors .....	63
VI. Intestinal Tract Glucagon Receptors .....	63
E. Tissue Distribution of Glucagon Receptor Transcripts .....	63
F. Regulation of Glucagon Receptor Gene Expression .....	65
G. Structure/Function Analysis of the Glucagon Receptor .....	67
H. Human Glucagon Receptor .....	69
I. Conclusions .....	70
References .....	70

## CHAPTER 5

**Mode of Action of Glucagon Revisited**

F. PECKER and C. PAVOINE. With 14 Figures .....	75
A. Introduction .....	75
B. Glucagon Actions Mediated Through Glucagon Receptors .....	76
I. Glucagon Receptor .....	76
II. Glucagon Action in Liver .....	77
1. Glucagon Mobilizes $\text{Ca}^{2+}$ in Hepatocytes .....	77
2. Glucagon Potentiates the Effect of $\text{Ca}^{2+}$ -Mobilizing Agonists .....	78
3. Regulation of the Cyclic-GMP-Inhibited Phosphodiesterase (CGI-PDE) by cAMP-Dependent Phosphorylation in Liver .....	79
III. Glucagon Action in Heart .....	79
1. Adenylyl Cyclase Activation Versus cAMP-Phosphodiesterase Inhibition in Heart Cells .....	79
C. Glucagon is Processed by Its Target Cells .....	83
D. Action of Mini-glucagon [Glucagon (19-29)] in Liver .....	85
I. Pharmacological Concentrations of Glucagon Inhibit the Liver Plasma Membrane $\text{Ca}^{2+}$ Pump .....	85
II. Mini-glucagon is the True Effector of the Liver Plasma Membrane $\text{Ca}^{2+}$ Pump .....	86
III. $\alpha$ - and $\beta\gamma$ -Subunits of G Protein Mediate Inhibition of the Liver $\text{Ca}^{2+}$ Pump by Mini-glucagon .....	87
E. Mini-glucagon Action in Heart .....	89
I. Mini-glucagon is a Component of the Positive Inotropic Effect of Glucagon .....	89
II. The Sarcolemmal $\text{Ca}^{2+}$ Pump, in Heart, Is a Target for Mini-glucagon Action .....	91
III. Mini-glucagon Produces Accumulation of $\text{Ca}^{2+}$ into the Sarcoplasmic Reticulum Stores .....	93
F. Glucagon and Mini-glucagon Act in Concert .....	94
G. Conclusion and Perspectives .....	96
References .....	98

## CHAPTER 6

**Pulsatility of Glucagon**

P. LEFÈVRE, G. PAOLISSO, and A.J. SCHEEN. With 3 Figures .....	105
A. Introduction .....	105
B. Oscillations in Glucagon Plasma Levels .....	105
I. Animal Studies .....	105
II. Human Studies .....	106
C. Pulsatile Glucagon Secretion In Vitro .....	106

D. Pulsatile Glucagon Delivery In Vitro .....	107
E. Pulsatile Glucagon Delivery In Vivo .....	107
I. Pulsatile Glucagon Administration in Normal Man .....	107
II. Combined Pulsatile Administration of Glucagon and Insulin in Normal Man .....	108
III. Pulsatile Administration of Glucagon in Diabetic Patients .....	109
IV. Pulsatile Administration of Glucagon in Dogs .....	109
F. Conclusions .....	112
References .....	112

## CHAPTER 7

### **Glucagon and Diabetes**

P.J. LEFÈBVRE .....	115
A. Introduction .....	115
B. Diabetogenic Effects of Glucagon .....	115
C. The A Cell in Diabetes .....	117
D. Circulating Glucagon Levels in Diabetes .....	117
E. Glucagon Dysfunction in Diabetes .....	118
I. Hyperglucagonemia of Diabetes .....	118
II. Defective Glucose Counterregulation .....	120
F. Role of Glucagon Excess in the Metabolic Abnormalities of Diabetes .....	121
I. Postpancreatectomy Diabetes .....	121
II. Insulin-Dependent Diabetes .....	121
III. Non-Insulin-Dependent Diabetes .....	122
G. Therapeutic Implications .....	123
I. Insulin-Dependent Diabetes .....	123
II. Non-Insulin-Dependent Diabetes .....	123
H. Conclusions .....	125
References .....	125

## CHAPTER 8

### **The Search for Glucagon Antagonists**

J.M. AMATRUDA and J.N. LIVINGSTON .....	133
A. Glucagon as a Drug Target .....	133
B. Search for a Glucagon Antagonist .....	135
I. Other Effects of Glucagon .....	135
II. Glucagon-Receptor Knockout Mice .....	136

Contents	XV
III. Targets for a Glucagon Antagonist	137
1. Synthesis, Processing and Secretion of Glucagon	137
2. Inhibition of the Actions of the Glucagon Receptor	139
IV. Humanized Mice	143
References	144

## CHAPTER 9

### **Glucagon and Glucose Counterregulation**

P.E. CRYER. With 2 Figures	149
A. Introduction	149
B. Glycemic Action of Glucagon	150
C. Glucagon Secretion	151
I. Regulatory Mechanisms	151
II. Glycemic Thresholds	153
D. Role of Glucagon in Glucose Counterregulation	153
I. Physiology	153
1. Insulin	153
2. Glucagon	154
3. Epinephrine	154
4. Other Counterregulatory Factors	154
II. Pathophysiology	155
E. Conclusions	155
References	156

## CHAPTER 10

### **Modes of Glucagon Administration**

G. SLAMA, D. BENNIS, and P. ZIRINIS. With 2 Figures	159
A. Introduction	159
B. Classic Routes of Administration	160
I. Intravenous Route	160
II. Intramuscular Route	160
III. Subcutaneous Route	161
C. New Routes of Glucagon Administration	162
I. Intranasal Route	162
II. Eye Drops	166
III. Rectal Route	167
D. Conclusions	168
References	169

## CHAPTER 11

**The Place of Glucagon in Emergency Medicine**

M.M. JOHNSON and G.P. ZALOGA .....	171
A. Hypoglycemia .....	171
B. Cardiovascular Insufficiency .....	174
C. Vascular Effects .....	178
D. Renal/Urologic Effects .....	180
E. Shock .....	180
F. Respiratory Effects .....	181
G. Gastrointestinal Effects .....	182
H. Radiographic Studies .....	184
I. Adverse Effects .....	184
References .....	184

## CHAPTER 12

**The Place of Glucagon in Medical Imaging**

J. SKUCAS .....	195
A. Introduction .....	195
B. Upper Gastrointestinal Tract .....	195
I. Esophagus .....	195
II. Stomach and Duodenum .....	196
C. Small Bowel .....	198
I. Enteroclysis .....	198
II. Retrograde Ileography .....	198
III. Peroral Pneumocolon .....	199
D. Large Bowel .....	199
I. Barium Enema .....	199
II. Intussusception Reduction .....	200
E. Biliary Tract .....	201
F. Other Applications .....	201
I. Computed Tomography .....	201
II. Ultrasonography .....	201
III. Angiography .....	202
IV. Magnetic Resonance Imaging .....	202
V. Hysterosalpingography .....	202
VI. Scintigraphy .....	203
VII. Urography .....	204
G. Side Effects and Contraindications .....	204
References .....	205

## CHAPTER 13

**The Glucagon Test for Evaluation of Insulin Secretion**

A. J. SCHEEN .....	211
A. Introduction .....	211
B. Methodological Aspects .....	211
I. Classical Test .....	211
II. Dose-Response Curve .....	212
III. Reproducibility .....	212
IV. Influence of Prevailing Glucose Level .....	213
V. Combined Stimulation .....	214
1. Glucagon-Glucose Test .....	214
2. Glucagon-Meal Test .....	214
C. Comparison with Other Stimuli .....	214
I. Oral Glucose Tolerance Test .....	214
II. Intravenous Glucose Tolerance Test .....	215
III. Meal .....	215
IV. Other Tests .....	216
D. Clinical Applications .....	216
I. Insulin-Dependent Diabetes Mellitus .....	216
II. Non-Insulin-Dependent Diabetes Mellitus .....	217
III. Hypoglycemia .....	217
IV. Other Diseases .....	218
E. Conclusions .....	218
References .....	219

## CHAPTER 14

**Glucagon and the Control of Appetite**

N. GEARY. With 2 Figures .....	223
A. Introduction .....	223
B. Prandial Glucagon Secretion .....	223
C. Glucagon Administration and Food Intake .....	225
I. Animal Studies .....	225
II. Human Studies .....	229
D. Glucagon Antagonism and Food Intake .....	229
E. Mechanism of Glucagon Satiety .....	231
I. Site of Action .....	231
II. Transduction .....	231
III. Hepatic Vagal Afferents .....	232
F. Clinical Aspects .....	233
I. Pathophysiology of Glucagon Satiety .....	233
II. Therapeutic Potential .....	233
G. Conclusions .....	234
References .....	234



## CHAPTER 15

**Glucagonoma and Its Management**

A.J. SCHEEN and P.J. LEFÈVRE .....	239
A. Introduction .....	239
B. Diagnosis and Localization of the Tumor .....	240
C. Management of the Glucagonoma Syndrome .....	242
I. Surgical Treatment .....	242
II. Vascular Occlusion .....	243
III. Radiation Therapy .....	243
IV. Chemotherapy .....	244
1. Streptozotocin .....	244
2. Dacarbazine .....	245
3. Others .....	246
V. Biological Therapy .....	246
VI. Antisecretory Peptide Therapy .....	247
VII. Symptomatic Treatment .....	248
D. Prognosis .....	248
E. Conclusions .....	249
References .....	250

## CHAPTER 16

**Structure and Function of the Glucagon-Like Peptide-1 Receptor**

B. THORENS and C. WIDMANN. With 7 Figures .....	255
A. Introduction .....	255
B. GLP-1 Receptor .....	256
I. Structure .....	256
II. Tissue Distribution .....	258
III. Binding Characteristics .....	261
1. GLP-1 and Related Peptides .....	261
2. Exendins .....	261
IV. Coupling to Intracellular Second Messengers .....	262
V. Cross-talk Between the GLP-1 and Glucose-Signaling Pathways .....	264
VI. GLP-1 Versus GIP in the Stimulation of Insulin Secretion .....	266
VII. Regulation of Receptor Function .....	267
1. Regulated Expression .....	267
2. Desensitization .....	267
3. Internalization .....	267
VIII. GLP-1 in Non-Insulin-Dependent Diabetes .....	268
C. Conclusions .....	268
References .....	269

CHAPTER 17

**Physiology and Pathophysiology of GLP-1**

B. GÖKE, R. GÖKE, H.-C. FEHMANN, and H.-P. BODE

With 5 Figures . . . . . 275

A. The Incretin Concept . . . . . 275

B. Origin, Processing, Secretion and Fate of GLP-1 . . . . . 277

    I. GLP-1 as Post-translational Product of Proglucagon  
        Processing in Gut, Postsecretory Fate . . . . . 277

    II. Secretion of GLP-1 . . . . . 280

C. Tissue Distribution of GLP-1 Receptors  
and Biological Actions . . . . . 282

    I. General . . . . . 282

    II. Endocrine Pancreas . . . . . 285

    III. Lung . . . . . 287

    IV. Stomach . . . . . 288

    V. Brain . . . . . 289

    VI. Adipose Tissue . . . . . 290

    VII. Skeletal Muscle . . . . . 291

    VIII. Others . . . . . 291

        1. Exocrine Pancreas . . . . . 291

        2. Liver . . . . . 291

D. Signal Transduction of the GLP-1 Receptor . . . . . 291

    I. cAMP Pathway . . . . . 291

    II. Calcium . . . . . 293

E. Pathophysiological Relevance? . . . . . 297

References . . . . . 298

CHAPTER 18

**Potential of GLP-1 in Diabetes Management**

J.J. HOLST, M.A. NAUCK, C.F. DEACON, and C. ØRSKOV

With 2 Figures . . . . . 311

A. Introduction . . . . . 311

B. Actions of GLP-1 on Blood Glucose in Humans . . . . . 314

C. Gastrointestinal Effects of GLP-1 in Humans . . . . . 315

D. GLP-1 and Diabetes . . . . . 316

    I. Secretion . . . . . 316

    II. Receptors . . . . . 316

    III. Effects . . . . . 317

E. GLP-1 Metabolism in Normal and Diabetic Subjects . . . . . 320

F. Conclusion and Outlook . . . . . 321

References . . . . . 322

## CHAPTER 19

**Oxyntomodulin and Its Related Peptides**

D. BATAILLE. With 5 Figures .....	327
A. Introduction .....	327
B. Biological Characteristics of Oxyntomodulin .....	327
I. Receptors .....	327
II. Acid Secretion .....	329
III. Biologically Active Moiety of Oxyntomodulin .....	330
IV. In Vivo Mode of Action: Interactions with Other Peptides .....	331
V. In Vitro Mode of Action .....	332
VI. Pharmacology: Search for a "Minimal Oxyntomodulin" ....	332
VII. Human Physiology and Pathophysiology: Oxyntomodulin-Like Immunoreactivity .....	333
VIII. Recent Developments .....	335
C. Conclusions .....	336
References .....	337
 <b>Subject Index</b> .....	 341